New Zealand has pulled out of plans to set up with Australia a joint drugs regulatory agency after the government admitted that it had failed to get sufficient support in Parliament to proceed.

Legislation to establish the Australia/New Zealand Therapeutic Goods

Agency (ANZTPA) is being shelved because “the government does not

have the numbers in Parliament to put in place a sensible, acceptable

compromise that would satisfy all parties at this time,” said New

Zealand State Services Minister Annette King. The Australian

government had agreed that suspending negotiations on the joint

authority “is a sensible course of action,” she added.

Back in December 2003, the two nations signed their original

agreement to replace Australia’s Therapeutic Goods Administration

and the New Zealand Medicines and Medical Devices Safety

Authority (Medsafe) with a single agency to regulate therapeutic

products, including medical devices and prescription, over-the-

counter and complementary medicines, in both countries.

The new Agency was planned to be up and running in 2005, and then by

mid-2006, but it has been dogged by controversy because of the

inclusion of complementary medicines in its remit, as these products

are not currently scrutinised by Medsafe. A massive opposition

campaign in New Zealand claimed that, under the new agency, herbal

remedies, dietary supplements and other complementary products would

be regulated by “Australian-dominated legislation” and that the cost

of meeting the new regulations would lead to the disappearance of 60%

of all products from the market, with the prices of those remaining

having to rise unacceptably.

Government attacked for wasting time and money

New Zealand’s opposition parties have broadly welcomed the bill’s

shelving, but have sharply attacked the Labour government for wasting

time and money on it. “Labour never listened to the legitimate concerns the complementary medicines industry, and other political parties, had about this bill,” said New Zealand National Party health spokesman Tony Ryall, while Peter Dunne, head of United Future New Zealand added: “Why the government decided in the first place to go ahead with the legislation and gave commitments to Australia that it could pass such a bill before it did any checking that it would have the Parliamentary numbers has always been beyond me. United Future supported the Bill's introduction only to allow its consideration by a select committee, but we had made it clear to them as long ago as last August that we did not support the mandatory

inclusion of complementary health products and natural medicines.”

And Green Party spokeswoman Sue Kedgley said of the Minister: “Had

she listened to the Health Select Committee four years ago, instead

of crashing on regardless, she would have saved millions of dollars

of taxpayers’ money. Serious questions need to be asked about the

huge waste of resources that has gone into pursuing this piece of

legislation. The Government has already spent at least seven million

dollars of taxpayers money on the agency.”

However, New Zealand’s Researched Medicines Industry Association

condemned “the intense, misleading and emotive lobbying” and “Third

World politicking” about complementaries which, it said, had ignored

the needs of seriously ill New Zealanders who need prescription

medicines.

“Do you know what you’ve done?” RMI chair Pippa MacKay asked Members

of Parliament. Medsafe “does not have the capacity to process

applications to register new medicines within a reasonable timeframe.

It currently takes an average of three years for a medicine to be

evaluated - more than twice as long as in Australia,” said Dr MacKay,

adding: “This unacceptable delay, along with last year's 800%

increase in fees, has meant that there have been only four

applications for the registration of new medicines since August last

year.”

NZ-ers 'missing out on new medicines'

The bill would have resolved existing medicines registration problems, but New Zealanders now risk missing out on new medicines available in the rest of the developed world, warned Dr MacKay. "It is a shame that those same people demand that food be regulated for safety reasons, yet somehow naively expect that the labels on complementary medicines

from unknown sources should be believed. The needs and interests of

the majority have been overridden by a tiny self-interested minority,” she added.

Medsafe’s official statements on the ANZTPA had acknowledged that New

Zealand's current regulatory framework for therapeutic products is

outdated and out of line with international best practice and that

its regulatory capacity is not sustainable even in the short-to mid-

term. “Establishing a new Authority with Australia has advantages for

both countries in terms of efficiency, making the most of scarce

technical expertise, sharing resources and reducing overall costs,”

it said.